Transthyretin amyloid cardiomyopathy (ATTR-CM) has evolved from an untreatable condition to one managed with three FDA-approved disease-modifying agents: tafamidis, acoramidis, and vutrisiran.
The FDA has granted Fast Track designation to ALXN2220, a novel depleter monoclonal antibody, for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.